Rallybio Corp

Research Rallybio Corp (RLYB) on Bullrun: market cap USD 84.96M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRLYB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 84.96M
• Financial periodFY2025
• RevenueUSD 858.00K
• Revenue growth34.9%
• Net income-USD 8.98M

Valuation Snapshot

latest market cap is USD 84.96M.

About Rallybio Corp

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Frequently asked questions

What is Rallybio Corp's market cap?

Rallybio Corp's market capitalization is USD 84.96M.

What does Rallybio Corp do?

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.